Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan Receives EMA Orphan Drug Designation for Pulmonary Neuroendocrine Carcinomas

Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310) for the treatment of pulmonary neuroendocrine carcinomas (NECs). The designation, following a positive opinion from the EMA’s Committee for Orphan Medicinal Products (COMP), recognizes the severity of NECs and urgent need for novel therapies. Zoci, a DLL3-targeting antibody drug conjugate (ADC), is positioned to become Zai Lab’s first globally commercialized oncology product.

Regulatory Milestone Overview

Product Profile & Therapeutic Innovation

Zoci (Zocilurtatug Pelitecan) Characteristics

• Drug Class: Novel DLL3-targeting antibody drug conjugate (ADC)
• Target: Delta-like ligand 3 (DLL3) – highly expressed in neuroendocrine tumors
• Mechanism: Combines tumor-specific targeting with potent cytotoxic payload delivery
• Development Stage: Advanced clinical development with global registration strategy
• Commercial Potential: First-in-class potential in high-unmet-need indication

Disease Context & Unmet Need

• Pulmonary NECs: Aggressive, rare malignancies with poor prognosis and limited treatment options
• Clinical Urgency: COMP recognition underscores severity and lack of effective therapies
• Patient Population: Ultra-rare disease qualifying for orphan drug incentives
• Current Standard: Limited efficacy with conventional chemotherapy regimens

Global Development Strategy & Registration Pathway

Planned Registration-Enabling Studies (by end of 2026)

1. Second- and Third-Line Small Cell Lung Cancer (SCLC)
2. First-Line Small Cell Lung Cancer (SCLC)
3. Extrapulmonary Neuroendocrine Carcinomas (epNECs)

Strategic Commercial Advantages

• Orphan Drug Benefits: 10-year market exclusivity in EU, protocol assistance, fee reductions
• Global Platform: DLL3 targeting applicable across multiple neuroendocrine tumor types
• First-Mover Position: Potential to establish standard of care in rare indications
• Partnership Readiness: Asset positioned for potential global commercial partnerships

Market Impact & Competitive Landscape

• Neuroendocrine Tumor Market: High-value segment with premium pricing potential for effective therapies
• DLL3 Target Validation: Emerging target with significant interest from major pharmaceutical companies
• ADC Technology Leadership: Demonstrates Zai Lab’s capability in next-generation targeted oncology
• Global Expansion Strategy: EMA ODD supports international regulatory filings beyond Europe
• Commercial Infrastructure: Foundation for building global oncology commercial capabilities

Strategic Outlook

The EMA Orphan Drug Designation for zoci represents a pivotal milestone in Zai Lab’s evolution from a China-focused biotech to a global oncology innovator. The DLL3-targeting ADC platform addresses critical unmet needs across multiple neuroendocrine tumor types, with pulmonary NECs serving as the initial regulatory beachhead. The planned triad of registration-enabling studies by year-end 2026 demonstrates aggressive global development strategy, while the orphan designation provides substantial commercial protection and regulatory support. This achievement validates Zai Lab’s innovative ADC platform and positions the company to potentially capture significant value in the high-unmet-need neuroendocrine carcinoma space.

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech